BiotechTube

L04RD1 + L04TD3

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Essential Hypertension

Conditions

Essential Hypertension

Trial Timeline

Jun 2, 2023 → Jun 29, 2023

NCT ID
NCT05993806

About L04RD1 + L04TD3

L04RD1 + L04TD3 is a phase 1 stage product being developed by Celltrion for Essential Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT05993806. Target conditions include Essential Hypertension.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05993806Phase 1Completed

Competing Products

20 competing products in Essential Hypertension

See all competitors
ProductCompanyStageHype Score
Azilsartan MedoxomilCelltrionPre-clinical
23
AZM X mg + AML Y mg + AZM X mg + AML Y' mg + AZM X' mg + AML Y mg + AZM X' mg + AML Y' mg + AZM X mg + AZM X' mg + AML Y mg + AML Y' mgCelltrionPhase 3
77
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
85
Anagre Cap.YuhanApproved
85
Telmisartan/Amlodipine/Chlorthalidone(Truset)YuhanPre-clinical
23
olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo + olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets + olmesartan medoxomil/hydrochlorothiazide tablets + olmesartan medoxomil/hydrochlorothiazide tabletsDaiichi SankyoPhase 3
77
olmesartan medoxomil + hydrochlorothiazide, if necessary + losartan + hydrochlorothiazide, if necessaryDaiichi SankyoPhase 3
77
CS8635 20/5/12.5mg and placebo + Olmetec® Plus 20/12.5mg and placeboDaiichi SankyoPhase 3
77
CS-3150 + olmesartan medoxomilDaiichi SankyoPre-clinical
23
olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo + Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo + olmesartan medoxomil + amlodipine + hydroclororthiazide + olmesartan medoxomil + amlodipine + hydroclororthiazide + olmesartan medoxomil + amlodipine + hydroclororthiazide + olmesartan medoxomil + amlodipine + olmesartan medoxomil + amlodipine + olmesartan medoxomil + amlodipineDaiichi SankyoPhase 3
77
Olmesartan medoxomil + Atenolol + Hydrochlorothiazide + olmesartan medoxomil + atenololDaiichi SankyoPhase 3
77
olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
85
CS-3150 + EplerenoneDaiichi SankyoPhase 3
77
olmesartan medoxomil + losartan potassiumDaiichi SankyoPhase 3
77
Olmesartan medoxomil 40 mg - Amlodipine 10 mg + Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg + Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg + OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg + OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg + OLM 40mg-AML 10mg-Hydrochlorothiazide 25mgDaiichi SankyoPhase 3
77
olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
85
Olmesartan medoxomil + Losartan + Furosemide oral tabletsDaiichi SankyoPhase 3
77
olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets + olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mgDaiichi SankyoPhase 3
77
olmesartan medoxomil + amlodipineDaiichi SankyoPhase 3
77
olmesartan medoxomil + amlodipine + hydrochlorothiazideDaiichi SankyoPhase 3
77

Other Products from Celltrion

Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85